DBV Technologies to Present at Upcoming Investor Conferences

Rhea-AI Summary

DBV Technologies, a clinical-stage biopharmaceutical company, announced that CEO Daniel Tassé will participate in two upcoming virtual investor conferences in June 2021. The first is at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 8:50am ET, followed by the JMP Life Sciences Conference on June 16, 2021, at 10:00am ET. A live webcast of these events will be available on the company's website, where replays will also be accessible later. DBV is focused on developing Viaskin™, a technology aimed at immunotherapy for food allergies.

Montrouge, France, June 2, 2021

DBV Technologies to Present at Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in upcoming virtual investor conferences in June.

Goldman Sachs Global Healthcare Conference
The fireside chat will take place on June 8, 2021 at 8:50am ET.

JMP Life Sciences Conference
The fireside chat will take place on June 16, 2021 at 10:00am ET.

A live webcast of the fireside chats will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/

A replay of the presentations will also be available on DBV Technologies’ website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

DBV Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

 

Attachment

• PDF Version

FAQ

When is DBV Technologies presenting at the Goldman Sachs Global Healthcare Conference?

DBV Technologies will present at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 8:50am ET.

What date will DBV Technologies speak at the JMP Life Sciences Conference?

DBV Technologies will participate in the JMP Life Sciences Conference on June 16, 2021, at 10:00am ET.

How can I watch the DBV Technologies investor conference presentations?

You can watch the live webcasts of DBV Technologies' presentations on their official website in the Investors & Media section.

What is the focus of DBV Technologies' Viaskin technology?

DBV Technologies' Viaskin technology is aimed at developing non-invasive immunotherapy solutions for food allergies.

Where can I find the replay of DBV Technologies' conference presentations?

Replays of DBV Technologies' conference presentations will be available on their official website after the events.